Addition of Biphasic Insulin Aspart 30 to Rosiglitazone in Type 2 Diabetes Mellitus That Is Poorly Controlled with Glibenclamide Monotherapy

Clinical Therapeutics

Volumn 25, Issue 12, 2003, Pages 3109-3123

  Raz, Itamar ^a   Mouritzen, Ulrik ^b   Vaz, Julius ^b   Hershkovitz, Tommy ^c   Wainstein, Julio ^d   Harman Boehm, Ilana ^e  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NOVO NORDISK A S   (Denmark)

^c WESTERN GALILEE HOSPITAL   (Israel)

^d WOLFSON MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

BIAsp 30; Glycemic control; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; FRUCTOSAMINE; GLIBENCLAMIDE; HEMOGLOBIN A1C; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATOLOGY; HUMAN; HYPOGLYCEMIA; IRRITABILITY; MALE; METABOLISM; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PALLOR; PARALLEL DESIGN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SWEATING; TITRIMETRY;

EID: 0346672386     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90095-6     Document Type: Article

References (35)

1. International Diabetes Federation (IDF). Diabetes Atlas. 2nd ed. Brussels, Belgium: IDF; 2003:11.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
3. Stratton IM, Adler AI, Neil HA, et al, for the United Kingdom Prospective Diabetes Study (UKPDS) Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
4. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabetic Med. 1996;13(Suppl 6):S19-S24.
5. Donahue RP, Abbott RD, Reed DM, Yano K, for the Honolulu Heart Program. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Diabetes. 1987;36:689-692.
6. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. European Diabetes Epidemiology Group. Lancet. 1999;354:617-621.
7. Fuller JH, Shipley M, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1:1373-1376.
8. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
9. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-Year follow-up in the Whitehall Study the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
10. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
11. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care. 1993;16(Suppl 3):90-100.
12. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-46.
13. Home PD, Lindholm A, Hylleberg B, Round P, for the UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904-1909.
14. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801-805.
15. Home PD, Lindholm A, Riis A, for the European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabetic Med. 2000;17:762-770.
16. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and Type 2 diabetic patients [published correction appears in Diabetic Med. 2002;19:797]. Diabetic Med. 2002;19:393-399.
17. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399-403.
18. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20:1612-1614.
19. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002;24:530-539.
20. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588.
21. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
22. Montgomery DC, ed. Design and Analysis of Experiments. 3rd ed. New York: Wiley; 1991:569-587.
23. Hollander M, ed. Nonparametric Statistical Methods. New York: Wiley; 1973:68-75.
24. Reinauer H, Home PD, Kanagasabapathy AS, Heuck CC. Laboratory Diagnosis and Monitoring of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 2002. Available at: http://www.who.int/bct/Main_areas_of_work/DIL/ Lab_Tech/PDF_Documents/diabetes.pdf. Accessed November 24, 2003.
25. Andrews WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes. 1984;33:634-642.
26. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234.
27. Scarlett JA, Gray RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982;5:353-363.
28. Rossetti L. Glucose toxicity: The implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med. 1995;18:255-260.
29. Laedtke T, Kjems L, Porksen N, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab. 2000;279:E520-E528.
30. United Kingdom Prospective Diabetes Study Group, United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.
31. Kaplan F, Al-Majali K, Betteridge DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk. 2001;8:211-217.
32. Kilo C, Mezitis N, Nadeau D, et al. Dinnertime NovoLog Mix 70/30 in combination with metformin - A combination to use? Diabetes. 2002;51(Suppl 2):A130.
33. Kvapil M, Mikolajczyk-Swatko A, Ostergaard AH, Shestakova M. In patients with poorly controlled Type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination. Diabetologia. 2002;45(Suppl 2):A18.
34. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabetic Med. 2002;19:572-574.
35. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78:1088-1091.